APC1 Polypeptide Sensitizes Cancer Cells to Anti-Cancer Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for triple-negative breast cancer (TNBC), are limited due to the lack of specific targets and often result in severe side effects, as they were designed assuming metastatic tumors behave similarly across organs, and TNBC is aggressive with poor prognosis and limited treatment options.
Innovation Solution
Administration of an isolated polypeptide comprising the amino acid sequence denoted by SEQ ID NO: 1, termed APC1, which increases the responsiveness of cancer cells to anti-cancer agents by modulating the expression of cellular moieties such as HER2 and estrogen receptors, thereby sensitizing cancer cells to therapies like Kadcyla and tamoxifen.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic chemotherapy or radiotherapy is used to treat cancer, then tumor cells are killed, but serious side effects occur due to toxicity to normal cells
Solution Approach 1:
The patent uses a peptide (APC1) as an intermediary substance that modifies the cancer cell membrane to increase its susceptibility to anti-cancer agents. This mediator enables targeted sensitization of cancer cells without affecting normal cells, resolving the contradiction between treatment effectiveness and toxicity to healthy tissue.
Solution Approach 2:
The invention changes the physical-chemical parameters of the cancer cell surface by introducing the APC1 peptide, which alters membrane properties and increases permeability or recognition by anti-cancer agents. This parameter modification enhances drug effectiveness specifically in cancer cells while sparing normal cells from toxicity.
2Adaptability or versatility
If standard anti-cancer regimens are used for TNBC, then treatment is provided, but prognosis remains poor due to limited treatment options
Solution Approach 1:
The patent applies preliminary action by pre-treating cancer cells with the APC1 peptide before administering anti-cancer agents. This preliminary modification of the cell membrane creates enhanced susceptibility to subsequent treatment, expanding therapeutic options and improving prognosis for TNBC patients who have limited treatment choices.
3Object-affected harmful factors
If therapies targeting specific antigens are developed, then treatment specificity is improved, but the complexity of identifying and targeting specific antigens increases
Solution Approach 1:
The APC1 peptide serves as a universal modifier that can be applied to various cancer cell types to enhance their susceptibility to different anti-cancer agents. This multi-functional approach provides treatment specificity without requiring complex identification and development of cancer-specific antigens for each patient.
Data Source
AI summary
A combinational therapy for treatment of cancer. Compositions, methods and kits for treatment of cancer and for sensitizing cancer cells to a broad spectrum of anti-cancer agents.